20, 2025 from Shankar, G., Arkin, S., Cocea, L., et al
Key information and effects Retatrutide has shown significant weight-loss potential in clinical trials, producing greater reductions in body weight than current GLP-1-only medications
The molecule is Lilly's in-house design, descended from a line of Indiana University academic work (the DiMarchi group) that Lilly has systematically productized through tirzepatide and now retatrutide
Health Canada requires comprehensive quality data, manufacturing information, and stability testing results before granting market authorization
Previously, it has been found that the GLP-1 infusion in healthy subjects increases baseline and acetylcholine-induced vasodilatation 45
Fasting Methods: 16:8 method (16 hours fasting, 8 hours eating), alternate-day fasting, and the 5:2 method (five days normal eating, two days of reduced calories)